Rituximab as a treatment option for refractory endogenous anterior uveitis

Ophthalmic Res. 2007;39(3):184-6. doi: 10.1159/000103239. Epub 2007 May 25.

Abstract

Background: To report on anti-CD20 antibody therapy in a patient with uveitis refractive to immunosuppression therapy.

Methods: Case report with ophthalmoscopic, optical coherence tomography and fluorescein-angiographic findings.

Results: A 49-year-old woman was suffering from bilateral, noninfectious chronic anterior uveitis refractive to corticosteroids and immunosuppressive drugs. Bilateral visual acuity was 20/100 due to cataract and cystoid macular edema (CME). After treatment with rituximab, vision and CME improved, and uveitis was stable until the final visit (follow-up at 12 months).

Conclusion: The case report suggests that rituximab may be helpful for selected patients with chronic anterior uveitis refractive to corticosteroids and immunosuppressive medication.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Chronic Disease
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Infusions, Intravenous
  • Middle Aged
  • Ophthalmoscopy
  • Rituximab
  • Tomography, Optical Coherence
  • Uveitis, Anterior / drug therapy*
  • Uveitis, Anterior / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Immunologic Factors
  • Rituximab